Accuray Incorp Stock Price, News & Analysis

Accuray Incorporated (NASDAQ: ARAY) has partnered with C-RAD AB to introduce a new breast cancer treatment package for the Radixact® System, set to be unveiled at the ASTRO Annual Meeting in San Antonio, Texas, from October 23-26, 2022. This package features an integrated Deep Inspiration Breath Hold (DIBH) solution that enhances treatment precision and safety for breast cancer patients. Accuray's advancements in the Radixact System reflect their commitment to innovation in radiation therapy, particularly relevant during Breast Cancer Awareness Month.

Recent findings from the PACE-B trial published in The Lancet Oncology reveal that patients receiving CyberKnife SBRT for prostate cancer experience significantly fewer bladder side effects compared to those treated with conventional SBRT. The study's results, based on nearly 20 years of clinical data, suggest a notable reduction in late-grade bladder toxicities. This innovative treatment method, which administers high doses of radiation over fewer sessions, promises enhanced disease control with minimal long-term side effects, indicating a shift toward more patient-friendly radiation therapy options.

Accuray Incorporated (NASDAQ: ARAY) will host a key opinion leader (KOL) discussion for analysts and investors on October 24, 2022, during the American Society of Radiation Oncology (ASTRO) Annual Meeting. The event will be held both in-person and virtually, starting at 3:30 pm CT (4:30 pm ET). KOLs will discuss clinical innovation and share insights on Accuray’s technology. Attendees must register by October 18, 2022, with a replay available online after the event.

Accuray (NASDAQ: ARAY) has expanded its global presence by introducing the CyberKnife system in Africa, specifically at the Children's Cancer Hospital 57357 in Egypt and the Kenyatta University Teaching, Referral & Research Hospital in Kenya. This innovative robotic radiation therapy can treat various tumors in just 1 to 5 outpatient sessions, significantly reducing treatment time and improving patient quality of life. With cancer cases projected to rise sharply in these regions, this launch aims to enhance patient access to advanced radiation therapies and improve healthcare equity.

Accuray Incorporated (NASDAQ: ARAY) appointed Seth Blacksburg, M.D., MBA as the vice president and chief medical officer for the Americas on Sept. 14, 2022. Dr. Blacksburg will lead strategic clinical insights to enhance commercial growth in North and South America. He brings extensive expertise in radiation oncology and has a history of improving patient care while achieving hospital economic goals. Prior to Accuray, he led radiation medicine at Lenox Hill Hospital, achieving significant departmental growth. His appointment aims to expand access to Accuray's innovative radiation therapy solutions.

Accuray (ARAY) collaborates with Genolier Innovation Hub, a subsidiary of AEVIS Victoria SA, to enhance patient care through innovation in medical technology. The Hub, opening in early 2024 in Switzerland, aims to unite various sectors, including medtech and pharma, facilitating advancements in healthcare. It will provide training facilities for radiation therapy and promote collaborative research. Accuray's CyberKnife and Radixact Systems will be showcased, reinforcing their commitment to improving radiation therapy for cancer treatment.

Accuray Incorporated (NASDAQ: ARAY) reported FY22 revenue growth of 8.5%, totaling $429.9 million. The fourth quarter ended June 30, 2022, saw gross orders of $88.3 million and net revenue of $110.0 million. Despite a GAAP net loss of $3.5 million for Q4, there was an improved loss compared to last year. Adjusted EBITDA for FY22 was $22.8 million. The company’s ClearRT™ imaging technology won a prestigious award. However, the ending backlog decreased by 8.6% to $563.7 million.

Accuray Incorporated (NASDAQ: ARAY) will release its financial results for Q4 and fiscal year 2022, closing on June 30, 2022, on August 10, 2022, post-market. A conference call will follow at 1:30 p.m. PT/4:30 p.m. ET. Investors can access the call at (833) 316-0563 (USA) or (412) 317-5747 (International), with a replay available for one week. The webcast will be hosted on Accuray's Investor Relations website, remaining accessible until the Q1 results for fiscal year 2023 are announced. Accuray focuses on innovative radiation therapy solutions for oncology and neuro-radiosurgery.

Accuray Incorporated (NASDAQ: ARAY) announced new clinical studies at the 15th Congress of the International Stereotactic Radiosurgery Society in Milan, reinforcing the efficacy of its CyberKnife platform for neurological treatments. With nearly 50 abstracts presented, the data showcase the platform's capability to perform non-invasive radiosurgery across various conditions, including recurring tumors. Accuray’s commitment to ongoing research and development aims to enhance treatment precision and patient comfort while enabling clinicians to handle more cases efficiently.